Simple purification of adeno-associated virus-DJ for liver-specific gene expression

Yonsei Medical Journal

Volumn 57, Issue 3, 2016, Pages 790-794

  Liu, Jingjing ^a   Moon, Young Ah ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Inha University School of Medicine   (South Korea)

Author keywords

AAV DJ; Large scale production; Liver specific expression

Indexed keywords

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; CHEMICAL BINDING; GENE EXPRESSION; INJECTION; LIVER; NONHUMAN; VIRUS CAPSID; VIRUS PARTICLE; ANIMAL; C57BL MOUSE; CASE REPORT; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; HEP-G2 CELL LINE; HUMAN; METABOLISM; MOUSE; VIRUS GENOME;

CAPSID PROTEIN;

ANIMALS; CAPSID; CAPSID PROTEINS; DEPENDOVIRUS; GENE EXPRESSION; GENETIC VECTORS; GENOME, VIRAL; HEP G2 CELLS; HUMANS; LIVER; MICE; MICE, INBRED C57BL;

EID: 84961262569     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2016.57.3.790     Document Type: Article

References (20)

1. Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci U S A 1993;90:2812-6.
2. Becker TC, Noel RJ, Coats WS, Gómez-Foix AM, Alam T, Gerard RD, et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol 1994;43 Pt A:161-89.
3. Konz JO, Lee AL, Lewis JA, Sagar SL. Development of a purification process for adenovirus: controlling virus aggregation to improve the clearance of host cell DNA. Biotechnol Prog 2005;21:466-72.
4. Yang Y, Nunes FA, Berencsi K, Furth EE, Gönczöl E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994;91:4407-11.
5. Kozarsky KF, Wilson JM. Gene therapy of hypercholesterolemic disorders. Trends Cardiovasc Med 1995;5:205-9.
6. Jooss K, Turka LA, Wilson JM. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther 1998;5:309-19.
7. Mandel RJ, Rendahl KG, Spratt SK, Snyder RO, Cohen LK, Leff SE. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson’s disease. J Neurosci 1998;18:4271-84.
8. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000;24:257-61.
9. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-65.
10. Nakai H, Thomas CE, Storm TA, Fuess S, Powell S, Wright JF, et al. A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J Virol 2002;76:11343-9.
11. Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors. Nat Protoc 2006;1:1412-28.
12. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-7.
13. Gao G, Lu Y, Calcedo R, Grant RL, Bell P, Wang L, et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 2006;13:77-87.
14. Nakai H, Fuess S, Storm TA, Muramatsu S, Nara Y, Kay MA. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 2005;79:214-24.
15. Wang L, Calcedo R, Nichols TC, Bellinger DA, Dillow A, Verma IM, et al. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 2005;105:3079-86.
16. Inagaki K, Fuess S, Storm TA, Gibson GA, Mctiernan CF, Kay MA, et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006;14:45-53.
17. Grimm D, Zhou S, Nakai H, Thomas CE, Storm TA, Fuess S, et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 2003;102:2412-9.
18. Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 2008;82:5887-911.
19. Lerch TF, O’Donnell JK, Meyer NL, Xie Q, Taylor KA, Stagg SM, et al. Structure of AAV-DJ, a retargeted gene therapy vector: cryo-electron microscopy at 4.5 Å resolution. Structure 2012;20:1310-20.
20. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem 2002;277:9520-8.